¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¼º¸ðº´¿ø ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2019-06-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼­¿ï¼º¸ðº´¿ø ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2019-06-29
±³À°ÀÏÀÚ : 2019-06-29
±³À°Àå¼Ò : ¼­¿ï¼º¸ðº´¿ø º»°ü ÁöÇÏ1Ãþ ´ë°­´ç  
±³À°ÁÖÁ¦ : ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­ÁÂ
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½ÅÀÌ½Ä ¿¬±¸È¸  
´ã´çÀÚ : ½ÅÀ̽Ŀ¬±¸È¸ Áغñ»ç¹«±¹
¿¬¶ôó : 02-2258-6854  
À̸ÞÀÏ : muischwa@catholic.ac.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í »çÀüµî·Ï-Àü¹®ÀÇ(5¸¸¿ø), Àü°øÀÇ/°£È£»ç/±âŸ(2¸¸¿ø) / ÇöÀåµî·Ï-Àü¹®ÀÇ(6¸¸¿ø), Àü°øÀÇ/°£È£»ç/±âŸ(3¸¸¿ø)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-29 ´ë°­´ç 08:30~08:50 Non-HLA antibodies (anti-AT1R and anti-MICA)  ¹ÎÁö¿ø(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 08:50~09:10 Clinical application of epitope analysis  ¹Ú±Ýº¸·¡(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 09:10~09:30 Progression of osteoporosis after KT  ¹Ú¿ì¿µ(°è¸íÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 09:30~09:50 Deceased donor with acute kidney injury  ±èÁ¤È£(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 09:50~10:10 IgA nephropathy  ÀÌÇÏÁ¤(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 10:10~10:30 Focal segmental glomerulosclerosis  ±èÈ¿»ó(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 10:50~11:10 Everolimus with reduced CNI exposure  Á¶ÀåÈñ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 11:10~11:30 CTLA4-Ig vs Calcineurin inhibitors  ±è¸í±Ô(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 11:30~12:10 Transplant pathology based on protocol biopsy  Ken Sakai(Toho University, Japan) 
±³À°½Ã°£ 06-29 ´ë°­´ç 12:10~12:50 Tacrolimus drug level variability  Min-Ju Wu(Taichung University, Taiwan) 
±³À°½Ã°£ 06-29 ´ë°­´ç 13:50~14:00 Recurrent ureterolithiasis after transplantation  ¹®½ÅÇ×(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 14:00~14:10 ³ú»çÀÚ °ø¿© À̽ĽÅÀå¿¡¼­ ¹ß°ßµÈ º¹ÇÕ¼º ½Å³¶Á¾  ±Ç¿ÀÇö (°è¸íÀÇ´ë) 
±³À°½Ã°£ 06-29 ´ë°­´ç 14:10~14:20 Acute uric acid nephropathy after rejection treatment  ¹Ú¿äÇÑ(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 14:20~14:30 52¼¼ ³²ÀÚ¿¡¼­ ½ÅÀå ÀÌ½Ä ÈÄ ÀÌ½Ä ½Å¿¡ ¹ß»ýÇÑ °á¼® Áõ·Ê  ±èÇظ®(Ãæ³²´ëÇб³º´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 14:30~14:40 Mesenchymal stem cell therapy for chronic AMR  ±èÇü´ö(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 14:40~14:50 Chronic active antibody-mediated rejection Áõ·Ê 1  ±è±âÇ¥(ºÐ´ç¼­¿ï´ë º´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 14:50~15:00 A Case of C4d-negative Active Antibody-Mediated Rejection in Baseline Low Titer DSA  ÀÓÁ¤ÈÆ(°æºÏ´ëÇб³º´¿ø ) 
±³À°½Ã°£ 06-29 ´ë°­´ç 15:00~15:10 Bortezomib treatment for chronic AMR  ±è¼º±Ô(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 15:10~15:20 Anamnestic response¿¡ ÀÇÇÑ severe antibody-mediated rejection  ±è±âÅÂ(BHSÇѼ­º´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 15:40~15:50 Synchronous CMV and HHV-8 gastritis  ±¸Á¤»ó(ÀüºÏ´ëÇб³º´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 15:50~16:00 ¹«Áõ»ó ±Þ¼º½Å¿ì½Å¿°À¸·Î ÀÎÇÑ À̽ĽŠ±â´É °¨¼Ò  À̹ÎÁ¤(¾ÆÁÖ´ëÇб³º´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 16:00~16:10 Fungal infection after KT from deceased donor  ±ÇÀ±Àç(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 16:10~16:20 ½ÅÀå À̽ÄÀ» ¹ÞÀº ȯÀÚ¿¡¼­ ½Å±«»ç¸¦ µ¿¹ÝÇÑ ½Å³ó¾ç  ÃÖ¿øÁ¤(Ãæ³²´ëÇб³º´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 16:20~16:30 Sirolimus induced pneumonitis  ¼­Çý¿ø(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 16:30~16:40 ½ÅÀåÀÌ½Ä ÈÄ Àç¹ßÇÑ IgA ½Åº´Áõ¿¡¼­ 2ÁÖ¸¶´Ù ½ºÅ×·ÎÀÌµå °í¿ë·® Ä¡·á¸¦ ÇÏ¿© È£ÀüµÈ ȯÀÚ 2¿¹   À±Á¤¾Æ(¼­¿ï ¾Æ»êº´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 16:40~16:50 KT in small bowel transplant recipient  À̼ö¾Æ(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 06-29 ´ë°­´ç 16:50~17:00 KT in patient with MYH9-related disease  ÀÌÈ­¿µ(Á¦ÁÖ´ëÇб³º´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¼º¸ðº´¿ø ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2019-06-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Á¦1Â÷ ¿¬±¸È¸ À¶ÇÕ ½ÉÆ÷Áö¾ö : 2019-06-29
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ( Carotid cavernous fistula) : 2019-06-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20362 ±¤ÁÖ Á¦77Â÷ ´ëÇÑÅëÁõÇÐȸ Çмú´ëȸ : 2024-05-25 0 21 2024-04-09
20361 °­¿ø ´ëÇÑ´ç´¢º´ÇÐȸ °­¿øÁöȸ Á¦7ȸ ´ç´¢º´±³À°ÀÚ ¼¼¹Ì³ª : 2024-05-25 0 28 2024-04-09
20360 ¼­¿ï 2024³âµµ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Adult ADHD ½ÉÆ÷Áö¿ò : 2024-05-24 0 27 2024-04-09
20359 ¼­¿ï ´ëÇѾฮÇÐȸ Frontiers in Epithelial Transport 2024(2ÀÏÂ÷) : 2024-05-24 0 20 2024-04-09
20358 ¼­¿ï Á¦29Â÷ ´ëÇÑÀÇ·á°ü·Ã°¨¿°°ü¸®ÇÐȸ Çмú´ëȸ¿Í ¿¬¼ö±³À° (2ÀÏÂ÷) : 2024-05-24 0 12 2024-04-09
20357 ¼­¿ï »ï¼º¼­¿ïº´¿ø 2024³â Á¦3ȸ SMC Æó°íÇ÷¾Ð ½ÉÆ÷Áö¾ö: 2024-05-24 0 41 2024-04-09
20356 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚµÈ ÀÌ°ú Áúȯ : 2024-05-23 0 25 2024-04-09
20355 ¼­¿ï ´ëÇѾฮÇÐȸ Frontiers in Epithelial Transport 2024(1ÀÏÂ÷) : 2024-05-23 0 21 2024-04-09
20354 ¼­¿ï Á¦29Â÷ ´ëÇÑÀÇ·á°ü·Ã°¨¿°°ü¸®ÇÐȸ Çмú´ëȸ¿Í ¿¬¼ö±³À° (1ÀÏÂ÷) : 2024-05-23 0 13 2024-04-09
20353 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-05-20 0 26 2024-04-09
20352 ¼­¿ï 2024³â ´ëÇѳ²¼º°Ç°­°»³â±âÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 75 2024-04-03
20351 ´ëÀü Áö¹æ°£°ú ¸¸¼º °£ÁúȯÀÇ °ü¸® ¿¬¼ö±³À° : 2024-05-19 0 99 2024-04-03
20350 ¼­¿ï 2024³â ´ëÇÑÁ¤¸ÆÅëÁõÇÐȸ Á¦6Â÷ Ãá°è Çмú´ëȸ : 2024-05-19 0 86 2024-04-03
20349 ¼­¿ï Á¦36Â÷ ÃÖ¼Òħ½À¼ºÇü¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-19 0 41 2024-04-03
20348 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ³»ºÐºñ³»°ú ¿¬¼ö°­Á : 2024-05-19 0 82 2024-04-03
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷